SCOPUS 정보 검색 플랫폼

Journal of the National Cancer Institute

Volumn 105, Issue 8, 2013, Pages 513-514

The effect of estrogen plus progestin hormone therapy on breast cancer mortality: Still unresolved

(2) Schairer, Catherine a Brinton, Louise A a

a NATIONAL CANCER INSTITUTE (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ESTROGEN; ESTROGEN PLUS PROGESTIN; GESTAGEN; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; EDITORIAL; FOLLOW UP; HUMAN; MAMMOGRAPHY; MENOPAUSE; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; PROGESTINS;

EID: 84876534926 PISSN: 00278874 EISSN: 14602105 Source Type: Journal
DOI: 10.1093/jnci/djt058 Document Type: Editorial

Times cited : (3)

References (10)

1
- 84876551405
- Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative Observational Study
- Chlebowski RT, Manson JE, Anderson GL, et al. Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative Observational Study. J Natl Cancer Inst. 2013;105(8):526-535.
- (2013) J Natl Cancer Inst , vol.105 , Issue.8 , pp. 526-535
- Chlebowski, R.T.¹ Manson, J.E.² Anderson, G.L.³

2
- 0037125379
- Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial
- Writing Group for the Women's Health Initiative Investigators
- Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA. 2002;288(3):321-333.
- (2002) JAMA , vol.288 , Issue.3 , pp. 321-333

3
- 0037830132
- Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: The women's health initiative randomized trial
- DOI 10.1001/jama.289.24.3243
- Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial. JAMA. 2003;289 (24):3243-3253. (Pubitemid 37430077)
- (2003) Journal of the American Medical Association , vol.289 , Issue.24 , pp. 3243-3253
- Chlebowski, R.T.¹ Hendrix, S.L.² Langer, R.D.³ Stefanick, M.L.⁴ Gass, M.⁵ Lane, D.⁶ Rodabough, R.J.⁷ Gilligan, M.A.⁸ Cyr, M.G.⁹ Thomson, C.A.¹⁰ Khandekar, J.¹¹ Petrovitch, H.¹² McTiernan, A.¹³

4
- 33748119290
- Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin
- DOI 10.1016/j.maturitas.2006.05.004, PII S0378512206001927
- Anderson GL, Chlebowski RT, Rossouw JE, et al. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin. Maturitas. 2006;55(2):103-115. (Pubitemid 44307491)
- (2006) Maturitas , vol.55 , Issue.2 , pp. 103-115
- Anderson, G.L.¹ Chlebowski, R.T.² Rossouw, J.E.³ Rodabough, R.J.⁴ McTiernan, A.⁵ Margolis, K.L.⁶ Aggerwal, A.⁷ David Curb, J.⁸ Hendrix, S.L.⁹ Allan Hubbell, F.¹⁰ Khandekar, J.¹¹ Lane, D.S.¹² Lasser, N.¹³ Lopez, A.M.¹⁴ Potter, J.¹⁵ Ritenbaugh, C.¹⁶

5
- 43249111337
- Estrogen plus progestin therapy and breast cancer in recently postmenopausal women
- DOI 10.1093/aje/kwn044
- Prentice RL, Chlebowski RT, Stefanick ML, et al. Estrogen plus progestin therapy and breast cancer in recently postmenopausal women. Am J Epidemiol. 2008;167(10):1207-1216. (Pubitemid 351670642)
- (2008) American Journal of Epidemiology , vol.167 , Issue.10 , pp. 1207-1216
- Prentice, R.L.¹ Chlebowski, R.T.² Stefanick, M.L.³ Manson, J.E.⁴ Pettinger, M.⁵ Hendrix, S.L.⁶ Hubbell, F.A.⁷ Kooperberg, C.⁸ Kuller, L.H.⁹ Lane, D.S.¹⁰ McTiernan, A.¹¹ Jo O'Sullivan, M.¹² Rossouw, J.E.¹³ Anderson, G.L.¹⁴

6
- 40449104676
- Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin
- DOI 10.1001/jama.299.9.1036
- Heiss G, Wallace R, Anderson GL, et al. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA. 2008;299(9):1036-1045. (Pubitemid 351347060)
- (2008) JAMA - Journal of the American Medical Association , vol.299 , Issue.9 , pp. 1036-1045
- Heiss, G.¹ Wallace, R.² Anderson, G.L.³ Aragaki, A.⁴ Beresford, S.A.A.⁵ Brzyski, R.⁶ Chlebowski, R.T.⁷ Gass, M.⁸ LaCroix, A.⁹ Manson, J.E.¹⁰ Prentice, R.L.¹¹ Rossouw, J.¹² Stefanick, M.L.¹³

7
- 67650021834
- Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause
- Prentice RL, Manson JE, Langer RD, et al. Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol. 2009;170(1):12-23.
- (2009) Am J Epidemiol , vol.170 , Issue.1 , pp. 12-23
- Prentice, R.L.¹ Manson, J.E.² Langer, R.D.³

8
- 59749098583
- Breast cancer after use of estrogen plus progestin in postmenopausal women
- Chlebowski RT, Kuller LH, Prentice RL, et al. Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med. 2009;360(6):573-587.
- (2009) N Engl J Med , vol.360 , Issue.6 , pp. 573-587
- Chlebowski, R.T.¹ Kuller, L.H.² Prentice, R.L.³

9
- 77958138780
- Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women
- Chlebowski RT, Anderson GL, Gass M, et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA. 2010;304(15):1684-1692.
- (2010) JAMA , vol.304 , Issue.15 , pp. 1684-1692
- Chlebowski, R.T.¹ Anderson, G.L.² Gass, M.³

10
- 55849143294
- Menopausal hormone therapy and breast cancer risk in the NIH-AARP diet and health study cohort
- Brinton LA, Richesson D, Leitzmann MF, et al. Menopausal hormone therapy and breast cancer risk in the NIH-AARP diet and health study cohort. Cancer Epidemiol Biomarkers Prev. 2008;17(11):3150-3160.
- (2008) Cancer Epidemiol Biomarkers Prev , vol.17 , Issue.11 , pp. 3150-3160
- Brinton, L.A.¹ Richesson, D.² Leitzmann, M.F.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.